Quarterly report [Sections 13 or 15(d)]

Consolidated Statements of Operations (Unaudited)

v3.25.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Net Revenue $ 1,853,597 $ 2,406,391
Operating expenses:    
Direct costs and expenses 1,367,860 1,573,441
Research and development 367,386 393,639
Clinical development 138,353 48,960
Selling, general and administrative 2,452,549 2,185,944
Depreciation and amortization 154,588 149,637
Total operating expenses 4,480,736 4,351,621
Loss from operations (2,627,139) (1,945,230)
Other income (expense):    
Interest income 542 6,127
Interest expense (15,485) (23,550)
Other income 2 4,510
Other expense (9,642)
Total other expense (24,583) (12,913)
Net loss before provision for income taxes (2,651,722) (1,958,143)
Income tax expense (8,695) (3,672)
Net loss $ (2,660,417) $ (1,961,815)
Net loss per common share, basic $ (0.16) $ (0.20)
Net loss per common share, diluted $ (0.16) $ (0.20)
Weighted average common shares outstanding, basic 16,257,456 9,915,426
Weighted average common shares outstanding, diluted 16,257,456 9,915,426